PRRT2 and acute myeloid leukemia: Interestingly, they found that resistance to PI3K/mTOR inhibition correlated with a fair number of PKC sites, leading to the conclusion that acute myeloid leukemia-derived cell lines use PKC pathways to proliferate, thus explaining the resistance to PI3K/mTOR inhibition.